20/20 Biolabs annual gross margin
2023
2024
2025
20/20 Biolabs Gross Margin Growth & History (AIDX)
20/20 Biolabs's gross margin was 29.56% for fiscal 2025.
View full 20/20 Biolabs company overview20/20 Biolabs annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 29.56% | +9.00 pp |
| 2024 | 2024-12-31 | 20.56% | +12.90 pp |
| 2023 | 2023-12-31 | 7.66% | — |
20/20 Biolabs quarterly gross margin
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 41.71% | +11.20 pp |
| Q1 2026 | 2026-03-31 | 17.80% | −12.14 pp |
| Q4 2025 | 2025-12-31 | 24.23% | −6.18 pp |
| Q3 2025 | 2025-09-30 | 34.71% | — |
| Q2 2025 | 2025-06-30 | 30.51% | — |
| Q1 2025 | 2025-03-31 | 29.94% | — |
| Q4 2024 | 2024-12-31 | 30.41% | — |
20/20 Biolabs gross margin trends
Between the periods ended 2023-12-31 and 2025-12-31, 20/20 Biolabs's gross margin increased from 7.66% to 29.56%, a change of +21.90 percentage points. The latest reported quarter, Q2 2026, shows 41.71%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 20/20 Biolabs source filings ↗